Literature DB >> 32811623

A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.

David Farabee1, Timothy Condon2, Kevin A Hallgren3, Barbara McCrady2.   

Abstract

The high prevalence of opioid use among justice-involved adults make jails an exceptional setting to initiate opioid use disorder (OUD) treatment, but optimal strategies for delivering these interventions are still not well understood. The objective of this study was to conduct a randomized controlled trial to assess the effectiveness of extended-release naltrexone (XR-NTX, Vivitrol®; Alkermes Inc) alone or in conjunction with patient navigation (XR-NTX + PN) for jail inmates with OUD. We randomized a sample of 135 sentenced jail inmates with moderate to severe OUD to (1) XR-NTX only; (2) XR-NTX + PN; or (3) enhanced treatment-as-usual (ETAU) with drug education, each initiated prior to release from jail. We scheduled follow-up data assessments at 1, 3, 6, and 12 months post-release. Primary outcomes were opioid use (based on Timeline Followback Interview and Addiction Severity Index) and meeting CIDI DSM-5 criteria for OUD 6 months postrelease. We also measured treatment adherence, HIV risk, and recidivism. XR-NTX participants received a mean of 2.26 of 7 possible injections compared to XR-NTX + PN participants, who received a mean of 2.93 injections (Cohen's d = 0.33, 95% CI: -0.09 to 0.74). Thirty-six percent of patients in XR-NTX + PN attended at least one postrelease PN session. We found no significant differences by study condition six months after release from jail for the primary outcomes of any opioid use (ETAU: 17%, XR-NTX: 16%, XR-NTX + PN: 29%) and past 30-day OUD (ETAU: 8%, XR-NTX: 11%, XR-NTX + PN: 10%). Secondary outcomes of rearrest and HIV risk also were similar across groups, with the exception of lower sex-related HIV risk among those in the XR-NTX condition at 12 months. This study did not show superior outcomes of XR-NTX or XR-NTX + PN with regard to opioid use or recidivism outcomes, relative to ETAU. It did, however, highlight the difficulties with adherence to XR-NTX and PN interventions in OUD patients initiating treatment in jail.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Experimental; Extended release naltrexone; Injectable naltrexone; Jail inmates; Opioid dependence

Mesh:

Substances:

Year:  2020        PMID: 32811623      PMCID: PMC7438599          DOI: 10.1016/j.jsat.2020.108076

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  18 in total

1.  Missing data in alcohol clinical trials: a comparison of methods.

Authors:  Kevin A Hallgren; Katie Witkiewitz
Journal:  Alcohol Clin Exp Res       Date:  2013-07-24       Impact factor: 3.455

2.  Release from prison--a high risk of death for former inmates.

Authors:  Ingrid A Binswanger; Marc F Stern; Richard A Deyo; Patrick J Heagerty; Allen Cheadle; Joann G Elmore; Thomas D Koepsell
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Naltrexone as negative reinforcement comments on "A behavioral analysis of coerced treatment for addicted offenders".

Authors:  David Farabee
Journal:  J Subst Abuse Treat       Date:  2006-09

4.  Extended-release naltrexone for opioid use disorder started during or following incarceration.

Authors:  Thomas Lincoln; Benjamin D Johnson; Patrick McCarthy; Ellen Alexander
Journal:  J Subst Abuse Treat       Date:  2017-04-06

Review 5.  Pharmacological interventions for drug-using offenders.

Authors:  Amanda E Perry; Matthew Neilson; Marrissa Martyn-St James; Julie M Glanville; Rebecca Woodhouse; Christine Godfrey; Catherine Hewitt
Journal:  Cochrane Database Syst Rev       Date:  2015-06-02

6.  Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use.

Authors:  Sean M Robinson; Linda Carter Sobell; Mark B Sobell; Gloria I Leo
Journal:  Psychol Addict Behav       Date:  2012-12-31

7.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

Review 8.  Patient navigation: state of the art or is it science?

Authors:  Kristen J Wells; Tracy A Battaglia; Donald J Dudley; Roland Garcia; Amanda Greene; Elizabeth Calhoun; Jeanne S Mandelblatt; Electra D Paskett; Peter C Raich
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

9.  Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

Authors:  Joshua D Lee; Peter D Friedmann; Timothy W Kinlock; Edward V Nunes; Tamara Y Boney; Randall A Hoskinson; Donna Wilson; Ryan McDonald; John Rotrosen; Marc N Gourevitch; Michael Gordon; Marc Fishman; Donna T Chen; Richard J Bonnie; James W Cornish; Sean M Murphy; Charles P O'Brien
Journal:  N Engl J Med       Date:  2016-03-31       Impact factor: 91.245

10.  The Effect of Patient Navigation on the Likelihood of Engagement in Clinical Care for HIV-Infected Individuals Leaving Jail.

Authors:  Janet J Myers; Mi-Suk Kang Dufour; Kimberly A Koester; Mark Morewitz; Rebecca Packard; Kate Monico Klein; Milton Estes; Brie Williams; Alissa Riker; Jacqueline Tulsky
Journal:  Am J Public Health       Date:  2018-01-18       Impact factor: 9.308

View more
  6 in total

1.  Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.

Authors:  Ali Jalali; Philip J Jeng; Daniel Polsky; Sabrina Poole; Yi-Chien Ku; George E Woody; Sean M Murphy
Journal:  J Subst Abuse Treat       Date:  2022-07-02

Review 2.  Scoping review of interventions to link individuals to substance use services at discharge from jail.

Authors:  Christine E Grella; Erika Ostlie; Dennis P Watson; Christy K Scott; John Carnevale; Michael L Dennis
Journal:  J Subst Abuse Treat       Date:  2022-01-04

3.  Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS).

Authors:  Elizabeth Needham Waddell; Sandra A Springer; Lisa A Marsch; David Farabee; Robert P Schwartz; Amesika Nyaku; Rusty Reeves; Keith Goldfeld; Ryan D McDonald; Mia Malone; Anna Cheng; Elizabeth C Saunders; Laura Monico; Jan Gryczynski; Kathleen Bell; Kasey Harding; Sandra Violette; Thomas Groblewski; Wendy Martin; Kasey Talon; Nicole Beckwith; Andrew Suchocki; Randy Torralva; Jennifer P Wisdom; Joshua D Lee
Journal:  J Subst Abuse Treat       Date:  2021-04-08

4.  Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD.

Authors:  Michele Staton; Hannah K Knudsen; Sharon L Walsh; Carrie Oser; Erika Pike; Michelle Lofwall
Journal:  Health Justice       Date:  2021-02-05

5.  Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services.

Authors:  Shannon Gwin Mitchell; Caroline Harmon-Darrow; Elizabeth Lertch; Laura B Monico; Sharon M Kelly; James L Sorensen; Robert P Schwartz
Journal:  J Subst Abuse Treat       Date:  2021-03-04

Review 6.  Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.

Authors:  Virginia Perez-Macia; Mireia Martinez-Cortes; Jesus Mesones; Manuel Segura-Trepichio; Lorena Garcia-Fernandez
Journal:  Patient Prefer Adherence       Date:  2021-05-18       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.